Oncolytic viruses get a boost with first FDA-approval recommendation
Elie Dolgin • June 1, 2015
The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies.
Continue reading here.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.